An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
Terminated
Hoffmann-La Roche
2014-05-01
This prospective, national, multicenter, non-interventional study examined the use of triple
combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and
ribavirin in re-treating participants with genotype 1 chronic hepatitis C (CHC) infection.
Dosing and treatment duration were at the discretion of the investigator in accordance with
local clinical practice and local labeling. Participants were to be observed for the duration
of their triple combination therapy and for up to 24 weeks thereafter.
Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis
comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label
combination of simeprevir+ sofosbuvir without Ribavirin.
A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C
Withdrawn
Janssen Scientific Affairs, LLC
Phase 4
2014-08-01
This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and
simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses.
A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C
Withdrawn
University of California, San Francisco
Phase 4
2014-08-01
This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and
simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
